Literature DB >> 15590418

Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.

D Waltregny1, B North, F Van Mellaert, J de Leval, E Verdin, V Castronovo.   

Abstract

Histone deacetylases (HDACs) represent a large family of enzymes identified as key regulators of nucleosomal histone acetylation, a major epigenetic event that controls eukaryotic gene transcription. Inappropriate deacetylation mediated by HDACs has been associated with profound alterations in cellular biology. We have thus hypothesized that an altered HDAC expression may favor cancer development/progression. To test this possibility, we have sought to screen the expression profiles of several class I and class II HDACs (HDAC1-8) in DU-145, PC-3 and LNCaP human prostate cancer cell lines as well as in matched malignant and non-malignant prostate tissues by use of real time RT-PCR, immunoblot and immunohistochemistry. All HDAC transcripts tested were detected at various levels in all prostate cancer cell lines and tissue samples analyzed. In prostate tissues, the abundance of HDAC1 protein, which was exclusively expressed in the cell nucleus, was similar in normal and malignant epithelial cells, but was usually lower in stromal cells. Unexpectedly, HDAC8, another class I HDAC, was not detected in epithelial cells but was uniquely expressed in the cytoplasm of stromal cells. HDAC5, a class II HDAC involved in myogenesis, was not detected in the tissues. Altogether, our findings indicate that epithelial and stromal cells exhibit distinct class I HDAC expression profiles, and the abundance of HDAC1 is not altered in human prostate cancer. In addition, our observations are the first to demonstrate the prominently cytosolic distribution of a class I HDAC, HDAC8.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15590418

Source DB:  PubMed          Journal:  Eur J Histochem        ISSN: 1121-760X            Impact factor:   3.188


  29 in total

Review 1.  Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Authors:  Dharam Kaushik; Vishal Vashistha; Sudhir Isharwal; Soud A Sediqe; Ming-Fong Lin
Journal:  Ther Adv Urol       Date:  2015-12

2.  Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study.

Authors:  Mitali Pandey; Parminder Kaur; Sanjeev Shukla; Ata Abbas; Pingfu Fu; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

3.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

Authors:  Yu-Wei Chou; Nagendra K Chaturvedi; Shougiang Ouyang; Fen-Fen Lin; Dharam Kaushik; Jue Wang; Isaac Kim; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2011-07-22       Impact factor: 8.679

4.  miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Varahram Shahryari; Sumit Arora; Mohd Saif Zaman; Inik Chang; Soichiro Yamamura; Yuichiro Tanaka; Takeshi Chiyomaru; Guoren Deng; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

5.  Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.

Authors:  Jing-Ya Sun; Ji-Dong Wang; Xin Wang; Hong-Chun Liu; Min-Min Zhang; Yu-Chih Liu; Chen-Hua Zhang; Yi Su; Yan-Yan Shen; Yue-Wei Guo; Ai-Jun Shen; Mei-Yu Geng
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

Review 6.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

7.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

8.  Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.

Authors:  Madeleine S Q Kortenhorst; Sumit Isharwal; Paul J van Diest; Wasim H Chowdhury; Cameron Marlow; Michael A Carducci; Ronald Rodriguez; Robert W Veltri
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

9.  HDAC4 promotes growth of colon cancer cells via repression of p21.

Authors:  Andrew J Wilson; Do-Sun Byun; Shannon Nasser; Lucas B Murray; Kanyalakshmi Ayyanar; Diego Arango; Maria Figueroa; Ari Melnick; Gary D Kao; Leonard H Augenlicht; John M Mariadason
Journal:  Mol Biol Cell       Date:  2008-07-16       Impact factor: 4.138

Review 10.  The role of histone deacetylases in prostate cancer.

Authors:  Ata Abbas; Sanjay Gupta
Journal:  Epigenetics       Date:  2008-11-24       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.